Reyvow: A Migraine Treatment
The approval of Reyvow has been very significant, as it’s a breakthrough in the treatment of acute migraines and the first to be approved by the FDA in more than two decades.
Reyvow’s a drug that contains the active ingredient lasmiditan. Its mechanism of action is different than that of other drugs used in the acute treatment of migraine.
It’s a new class of treatment in cases of acute migraine and its novelty lies in the fact that it’s the only drug of its family with FDA approval. Because its a 5-HT1F receptor agonist, it acts both centrally and peripherally.
Several studies have taken place and the results have shown that a higher percentage of patients treated with Reyvow were migraine-free two hours after the first dose in comparison to study participants taking placebo.
What is a migraine?
A migraine’s a type of severe headache that generally affects more women. It’s a headache most often located in the middle of the head and usually involves other symptoms as well.
Among the symptoms linked to migraines are auras with nausea, vomiting, or sensitivity to light. Some migraines appear without aura; however, those that do have aura often prevent individuals from going on with their lives and significantly diminish the quality of their lives.
It’s common for migraine patients to undergo several phases of treatment. Experts even recommend combining drug treatment with alternative therapies or techniques, to try to take fewer drugs and thus avoid their side effects.
Is Reyvow safe?
The drug comes in tablets with two different concentrations, 50 mg, and 100 mg doses. The most common side effects are dizziness, tiredness, sedation, nausea, vomiting, and muscle weakness.
In addition, as the drug acts on the central nervous system, while you’re under treatment, you shouldn’t drive or perform tasks that require a lot of attention. For this reason, you should practice caution if you have to operate machinery for at least eight hours after taking Reyvow.
How does it work?
Lasmiditan binds to the 5-HT1F receptor and acts both centrally and peripherally. It works by reducing the release of substances called neuropeptides. In addition, it influences the pain pathways without vasoconstriction at the cerebral level.
The drug was approved based on the results obtained in Phase III studies involving a total of 3,177 patients who’d suffered from migraines, both with and without aura.
The FDA noted that the data obtained revealed that the percentage of patients whose symptoms were pain, nausea, and sensitivity to light was significantly lower among the patients who took lasmiditan.
In just two hours, and with a single dose, this drug has been able to quickly and completely eliminate pain. It’s also effective in controlling and relieving migraine-associated symptoms such as auras.
You may also be interested in: Natural Ways to Treat Migraines
Reyvow and migraine
Suffering from a migraine episode can make you unable to perform daily tasks. Migraine sufferers experience attacks that can be very intense and painful, forcing them to stop their daily activities.
With just one dose, Reyvow provides the ability to quickly and completely eliminate moderate to severe migraine pain in just two hours.
Reyvow’s a non-opioid and non-narcotic medication and, according to the data available at this time, its use doesn’t create physical dependence.
In general, the adverse effects that may occur while taking this medication are mild to moderate. The symptoms that may appear most frequently are:
- Tingling sensation or numbness
- Nausea and vomiting
Other precautions to keep in mind include the possibility that you may develop central nervous system depression or serotonin syndrome.
The difficulty of treating migraine
Reyvow’s a medication that reduces moderate to severe headache pain within two hours of taking it. It also has the advantage of not producing photophobia or nausea. Currently, it represents a breakthrough in the treatment of migraines, making it a good option for these patients.It might interest you...